April 12, 2021
Lenvatinib/Pembrolizumab Improves Survival in Advanced Endometrial Cancer BookmarkGeorge Lundberg, MD
The ASCO Post reports on new results from a clinical trial testing a combination of the drugs lenvatinib and pembrolizumab in people with advanced or recurrent endometrial cancer. The results show that, compared to standard chemotherapy, this drug combo improves both overall and progression-free survival—according to both statistical and clinical analysis.
October 22, 2020
ESMO 2019: Immunotherapy in Cervical and Endometrial Cancers BookmarkGeorge Lundberg, MD
Article from The ASCO Post curated by Contributing Editor George Lundberg, MD, who notes:
Recent clinical trial results show that immunotherapy—a type of treatment that boosts the immune system to fight cancer—provided long-lasting, improved outcomes for patients with advanced cervical or endometrial cancer. These are important findings for difficult-to-treat cancers.
August 17, 2019
Endometrial Carcinoma—An Overview BookmarkGeorge Lundberg, MD
Curated by Editor in Chief George Lundberg, MD, who notes:There are two principal forms of uterine cancer: cervical and endometrial. Endometrial carcinoma is the most frequent cancer of the female genitalia in the developed world, with about 3% of U.S. women likely to receive such a diagnosis. This 2018 review from Medscape is comprehensive.